1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol

5 trials 3 recruiting

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

3 Recruiting

1 Completed trials

2 Sponsors

20 Countries

Phase III

Phase III: 5

Indications tested

Idiopathic pulmonary fibrosis 1

Sponsors using this IMP

Boehringer Ingelheim International GmbH 5 Boehringer Ingelheim Espana S.A. 4

All trials

5 total

A study to find out how nerandomilast is tolerated, handled by the body, and if it helps children and adolescents with interstitial lung dis… Pending

2025-523369-32-00 Phase III 5 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
A study to test whether nerandomilast can help slow down changes in the lung in people with a family history of pulmonary fibrosis Recruiting

2025-522383-33-00 Phase III 6 countries Boehringer Ingelheim International GmbH
A study to test whether nerandomilast helps people with lung fibrosis related to rheumatic diseases Recruiting

2024-512849-17-00 Phase III 7 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 10… Recruiting

2023-507353-15-00 Phase III 20 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH; Boehr…
A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Ended

2024-512803-37-00 Phase III 19 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH

Showing 1–5 of 5 trials

← All drugs A–Z